<p>在过去的 7 天里，美国市场上涨了 2.7%，过去一年上涨了 13%，预计未来几年盈利将年增长 15%。在这种情况下，投资者可能会发现低价股的价值——通常是较小或较新的公司——当其背靠强大的财务健康时，可以提供增长机会。尽管今天被视为一个小众领域，低价股仍然对那些寻求潜在隐藏价值和长期收益的人具有相关性；在这里，我们探讨三只结合了资产负债表韧性与良好前景的股票。</p>
<h3>美国十大低价股</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.35</td>
<td>$488.24M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.9265</td>
<td>$148M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.9326</td>
<td>$95.14M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Safe Bulkers (SB)</td>
<td>$3.66</td>
<td>$376.5M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>Flexible Solutions International (FSI)</td>
<td>$4.50</td>
<td>$55.08M</td>
<td>✅ 1 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8339</td>
<td>$6.1M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.77</td>
<td>$86.97M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Marine Petroleum Trust (MARP.S)</td>
<td>$4.43</td>
<td>$8.76M</td>
<td>✅ 1 ⚠️ 4 查看分析</td>
</tr>
<tr>
<td>TETRA Technologies (TTI)</td>
<td>$3.46</td>
<td>$441.8M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国低价股筛选器的 449 只股票的完整列表。</p>
<p>下面我们展示了一些通过我们的筛选器筛选出的股票。</p>
<h2>Nautilus Biotechnology (NAUT)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Nautilus Biotechnology, Inc. 是一家开发阶段的生命科学公司，专注于创建一种平台技术，以量化和解锁蛋白质组的复杂性，市值约为 1.009 亿美元。</p>
<p><strong>运营：</strong> Nautilus Biotechnology 尚未报告任何收入细分。</p>
<p><strong>市值：</strong> $100.09M</p>
<p>Nautilus Biotechnology 的市值为 1.009 亿美元，是一家面临低价股典型挑战的无收入生命科学公司。它最近收到了纳斯达克的通知，因未满足最低出价要求，但有直到 2025 年 10 月 28 日的时间来恢复合规。尽管没有债务且短期资产显著超过负债（1.416 亿美元对比 3330 万美元），但公司仍然处于亏损状态，五年内亏损年增长率为 20.5%，且近期没有盈利预测。预计收入将大幅增长，但预计三年内盈利将年下降 8.5%。</p>
<ul>
<li>点击这里查看完整的健康分析报告，以深入了解 Nautilus Biotechnology。</li>
<li>通过我们的详细增长报告评估 Nautilus Biotechnology 的未来盈利预期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/58e10862-26f1-4d48-a331-e7c060e3f438/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/58e10862-26f1-4d48-a331-e7c060e3f438/chart/debt-equity-history-analysis"/></p>
<p>NAUT 债务与股本历史及分析截至 2025 年 6 月</p>
<h2>BARK (BARK)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> BARK, Inc. 是一家以狗为中心的公司，提供狗的产品、服务和内容，市值约为 1.445 亿美元。</p>
<p><strong>运营：</strong> 公司的收入主要来自两个主要细分市场：商业，产生 6835 万美元，以及直接面向消费者，贡献 4158.4 万美元。</p>
<p><strong>市值：</strong> $144.5M</p>
<p>BARK, Inc.的市值为 1.445 亿美元，专注于以狗为中心的产品和服务，正在应对低价股典型的挑战。尽管处于亏损状态，并且预计在未来三年内不会实现盈利，但 BARK 显示出财务改善；其短期资产显著超过短期和长期负债。最近的收益显示，截止 2025 年 3 月 31 日的年度销售额略微下降至 4.8418 亿美元，而亏损相比去年有所缩小。由于宏观环境不确定，公司预计第一季度收入将下降，原因是减少了市场营销投入。</p>
<ul>
<li>点击这里访问我们完整的财务健康分析报告，以了解 BARK 的动态。</li>
<li>在这里了解 BARK 的未来增长轨迹。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/310671db-3ded-40ab-8e02-47d8d64d6d53/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/310671db-3ded-40ab-8e02-47d8d64d6d53/chart/revenue-and-expenses-breakdown"/></p>
<p>BARK 收入与支出细分截至 2025 年 6 月</p>
<h2>Seritage Growth Properties (SRG)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Seritage Growth Properties 是一家专注于美国各地多元化零售和混合用途物业的拥有、开发、重建、管理、销售和租赁的公司，市值约为 1.6559 亿美元。</p>
<p><strong>运营：</strong> 公司的收入细分主要涉及房地产物业，产生-341 万美元。</p>
<p><strong>市值：</strong> $165.59M</p>
<p>Seritage Growth Properties 的市值为 1.6559 亿美元，正在应对房地产领域低价股的复杂性。尽管持续亏损且五年内盈利下降，其 1.231 亿美元的短期资产显著超过短期负债，但与 2.4 亿美元的长期负债相比则显得不足。公司在五年内将债务从 157.9% 减少至 62.8%，并最近对其定期贷款设施进行了自愿提前还款，自 2021 年 12 月以来每年减少约 9940 万美元的利息支出，同时追求战略性销售计划，将其资产组合从大约 160 个减少至 15 个，自 2022 年 3 月以来。</p>
<ul>
<li>点击查看我们在 Seritage Growth Properties 财务健康报告中的详细分析。</li>
<li>查看我们的历史业绩报告，以获取 Seritage Growth Properties 的业绩记录的洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2c686c3d-1568-4c8d-95f7-aed1a96f409f/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2c686c3d-1568-4c8d-95f7-aed1a96f409f/chart/financial-position-analysis"/></p>
<p>截至 2025 年 6 月的 SRG 财务状况分析</p>
<h2>总结</h2>
<ul>
<li>在这里调查我们完整的 449 只美国便士股票。</li>
<li>对其他可能性感兴趣？通过提供可靠收入来源的稳健分红股票来多样化您的投资组合，以应对潜在的市场动荡。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

NAUT

<p>Nautilus Biotechnology 被认为是一个顶级的便士股票，尽管面临挑战，包括因未满足竞标价格要求而收到纳斯达克的通知。其市值为 1.0009 亿美元，仍处于亏损状态，亏损每年增加。过去一周，美国市场上涨了 2.7%，过去一年上涨了 13%，这引发了对便士股票的兴趣，期待其潜在增长。其他值得注意的便士股票包括 BARK, Inc. 和 Seritage Growth Properties，它们在各自领域中也面临类似的挑战</p>

<p>Over the last 7 days, the United States market has risen by 2.7%, and over the past year, it is up by 13%, with earnings expected to grow annually by 15% in the coming years. In light of these conditions, investors might find value in penny stocks—typically smaller or newer companies—that can offer growth opportunities when backed by strong financial health. Though considered a niche area today, penny stocks remain relevant for those seeking potential hidden value and long-term gains; here we explore three such stocks that combine balance sheet resilience with promising prospects.</p>
<div class="lb-trans"><p>在过去的 7 天里，美国市场上涨了 2.7%，过去一年上涨了 13%，预计未来几年盈利将年增长 15%。在这种情况下，投资者可能会发现低价股的价值——通常是较小或较新的公司——当其背靠强大的财务健康时，可以提供增长机会。尽管今天被视为一个小众领域，低价股仍然对那些寻求潜在隐藏价值和长期收益的人具有相关性；在这里，我们探讨三只结合了资产负债表韧性与良好前景的股票。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美国十大低价股</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.35</td>
<td>$488.24M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.9265</td>
<td>$148M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.9326</td>
<td>$95.14M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Safe Bulkers (SB)</td>
<td>$3.66</td>
<td>$376.5M</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Flexible Solutions International (FSI)</td>
<td>$4.50</td>
<td>$55.08M</td>
<td>✅ 1 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8339</td>
<td>$6.1M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.77</td>
<td>$86.97M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Marine Petroleum Trust (MARP.S)</td>
<td>$4.43</td>
<td>$8.76M</td>
<td>✅ 1 ⚠️ 4 View Analysis &gt;</td>
</tr>
<tr>
<td>TETRA Technologies (TTI)</td>
<td>$3.46</td>
<td>$441.8M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.35</td>
<td>$488.24M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.9265</td>
<td>$148M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.9326</td>
<td>$95.14M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Safe Bulkers (SB)</td>
<td>$3.66</td>
<td>$376.5M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>Flexible Solutions International (FSI)</td>
<td>$4.50</td>
<td>$55.08M</td>
<td>✅ 1 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.8339</td>
<td>$6.1M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.77</td>
<td>$86.97M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Marine Petroleum Trust (MARP.S)</td>
<td>$4.43</td>
<td>$8.76M</td>
<td>✅ 1 ⚠️ 4 查看分析</td>
</tr>
<tr>
<td>TETRA Technologies (TTI)</td>
<td>$3.46</td>
<td>$441.8M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 449 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国低价股筛选器的 449 只股票的完整列表。</p>
</div><p>Underneath we present a selection of stocks filtered out by our screen.</p>
<div class="lb-trans"><p>下面我们展示了一些通过我们的筛选器筛选出的股票。</p>
</div><h2>Nautilus Biotechnology (NAUT)</h2>
<div class="lb-trans"><h2>Nautilus Biotechnology (NAUT)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Nautilus Biotechnology, Inc. is a development stage life sciences company focused on creating a platform technology to quantify and unlock the complexity of the proteome, with a market cap of approximately $100.09 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Nautilus Biotechnology, Inc. 是一家开发阶段的生命科学公司，专注于创建一种平台技术，以量化和解锁蛋白质组的复杂性，市值约为 1.009 亿美元。</p>
</div><p><strong>Operations:</strong> Nautilus Biotechnology has not reported any revenue segments.</p>
<div class="lb-trans"><p><strong>运营：</strong> Nautilus Biotechnology 尚未报告任何收入细分。</p>
</div><p><strong>Market Cap:</strong> $100.09M</p>
<div class="lb-trans"><p><strong>市值：</strong> $100.09M</p>
</div><p>Nautilus Biotechnology, with a market cap of US$100.09 million, is a pre-revenue life sciences company facing challenges typical of penny stocks. It recently received notice from Nasdaq for not meeting the minimum bid price requirement but has until October 28, 2025, to regain compliance. Despite being debt-free and having short-term assets exceeding liabilities significantly (US$141.6 million vs. US$33.3 million), the company remains unprofitable with losses increasing at an annual rate of 20.5% over five years and no profitability forecast in the near term. Revenue is expected to grow substantially, yet earnings are projected to decline by 8.5% annually over three years.</p>
<div class="lb-trans"><p>Nautilus Biotechnology 的市值为 1.009 亿美元，是一家面临低价股典型挑战的无收入生命科学公司。它最近收到了纳斯达克的通知，因未满足最低出价要求，但有直到 2025 年 10 月 28 日的时间来恢复合规。尽管没有债务且短期资产显著超过负债（1.416 亿美元对比 3330 万美元），但公司仍然处于亏损状态，五年内亏损年增长率为 20.5%，且近期没有盈利预测。预计收入将大幅增长，但预计三年内盈利将年下降 8.5%。</p>
</div><ul>
<li>Jump into the full analysis health report here for a deeper understanding of Nautilus Biotechnology.</li>
<li>Assess Nautilus Biotechnology's future earnings estimates with our detailed growth reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里查看完整的健康分析报告，以深入了解 Nautilus Biotechnology。</li>
<li>通过我们的详细增长报告评估 Nautilus Biotechnology 的未来盈利预期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/58e10862-26f1-4d48-a331-e7c060e3f438/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/58e10862-26f1-4d48-a331-e7c060e3f438/chart/debt-equity-history-analysis"/></p>
<p>NAUT Debt to Equity History and Analysis as at Jun 2025</p>
<div class="lb-trans"><p>NAUT 债务与股本历史及分析截至 2025 年 6 月</p>
</div><h2>BARK (BARK)</h2>
<div class="lb-trans"><h2>BARK (BARK)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> BARK, Inc. is a dog-centric company offering products, services, and content for dogs with a market cap of approximately $144.50 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> BARK, Inc. 是一家以狗为中心的公司，提供狗的产品、服务和内容，市值约为 1.445 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived from two primary segments: Commerce, which generated $68.35 million, and Direct to Consumer, contributing $415.84 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自两个主要细分市场：商业，产生 6835 万美元，以及直接面向消费者，贡献 4158.4 万美元。</p>
</div><p><strong>Market Cap:</strong> $144.5M</p>
<div class="lb-trans"><p><strong>市值：</strong> $144.5M</p>
</div><p>BARK, Inc., with a market cap of US$144.50 million, is navigating the challenges typical of penny stocks with a focus on dog-centric products and services. Despite being unprofitable and not expected to achieve profitability in the next three years, BARK has shown financial improvements; its short-term assets exceed both short-term and long-term liabilities significantly. Recent earnings revealed a slight decline in sales to US$484.18 million for the year ended March 31, 2025, while losses have narrowed compared to the previous year. The company anticipates lower first-quarter revenue due to reduced marketing efforts amid uncertain macro conditions.</p>
<div class="lb-trans"><p>BARK, Inc.的市值为 1.445 亿美元，专注于以狗为中心的产品和服务，正在应对低价股典型的挑战。尽管处于亏损状态，并且预计在未来三年内不会实现盈利，但 BARK 显示出财务改善；其短期资产显著超过短期和长期负债。最近的收益显示，截止 2025 年 3 月 31 日的年度销售额略微下降至 4.8418 亿美元，而亏损相比去年有所缩小。由于宏观环境不确定，公司预计第一季度收入将下降，原因是减少了市场营销投入。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of BARK.</li>
<li>Learn about BARK's future growth trajectory here.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们完整的财务健康分析报告，以了解 BARK 的动态。</li>
<li>在这里了解 BARK 的未来增长轨迹。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/310671db-3ded-40ab-8e02-47d8d64d6d53/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/310671db-3ded-40ab-8e02-47d8d64d6d53/chart/revenue-and-expenses-breakdown"/></p>
<p>BARK Revenue &amp; Expenses Breakdown as at Jun 2025</p>
<div class="lb-trans"><p>BARK 收入与支出细分截至 2025 年 6 月</p>
</div><h2>Seritage Growth Properties (SRG)</h2>
<div class="lb-trans"><h2>Seritage Growth Properties (SRG)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Seritage Growth Properties is a company focused on the ownership, development, redevelopment, management, sale and leasing of diversified retail and mixed-use properties across the United States with a market cap of approximately $165.59 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Seritage Growth Properties 是一家专注于美国各地多元化零售和混合用途物业的拥有、开发、重建、管理、销售和租赁的公司，市值约为 1.6559 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue segment primarily involves real estate properties, which generated -$3.41 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入细分主要涉及房地产物业，产生-341 万美元。</p>
</div><p><strong>Market Cap:</strong> $165.59M</p>
<div class="lb-trans"><p><strong>市值：</strong> $165.59M</p>
</div><p>Seritage Growth Properties, with a market cap of US$165.59 million, is navigating the complexities of penny stocks in the real estate sector. Despite ongoing unprofitability and declining earnings over five years, its short-term assets of US$123.1 million exceed short-term liabilities significantly but fall short against long-term liabilities of US$240 million. The company has reduced its debt substantially from 157.9% to 62.8% over five years and recently made a voluntary prepayment on its term loan facility, reducing annual interest expenses by approximately US$99.4 million since December 2021 while pursuing a strategic Plan of Sale reducing its portfolio to 15 assets from approximately 160 since March 2022.</p>
<div class="lb-trans"><p>Seritage Growth Properties 的市值为 1.6559 亿美元，正在应对房地产领域低价股的复杂性。尽管持续亏损且五年内盈利下降，其 1.231 亿美元的短期资产显著超过短期负债，但与 2.4 亿美元的长期负债相比则显得不足。公司在五年内将债务从 157.9% 减少至 62.8%，并最近对其定期贷款设施进行了自愿提前还款，自 2021 年 12 月以来每年减少约 9940 万美元的利息支出，同时追求战略性销售计划，将其资产组合从大约 160 个减少至 15 个，自 2022 年 3 月以来。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Seritage Growth Properties' financial health report.</li>
<li>Review our historical performance report to gain insights into Seritage Growth Properties' track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击查看我们在 Seritage Growth Properties 财务健康报告中的详细分析。</li>
<li>查看我们的历史业绩报告，以获取 Seritage Growth Properties 的业绩记录的洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2c686c3d-1568-4c8d-95f7-aed1a96f409f/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/2c686c3d-1568-4c8d-95f7-aed1a96f409f/chart/financial-position-analysis"/></p>
<p>SRG Financial Position Analysis as at Jun 2025</p>
<div class="lb-trans"><p>截至 2025 年 6 月的 SRG 财务状况分析</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Investigate our full lineup of 449 US Penny Stocks right here.</li>
<li>Interested In Other Possibilities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里调查我们完整的 449 只美国便士股票。</li>
<li>对其他可能性感兴趣？通过提供可靠收入来源的稳健分红股票来多样化您的投资组合，以应对潜在的市场动荡。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

Nautilus Biotechnology 在我们评选的前三名便士股票中名列前茅